17-17793779-CCAGCAG-C
Position:
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBA1
The NM_030665.4(RAI1):βc.867_872delβ(p.Gln290_Gln291del) variant causes a inframe deletion change. The variant allele was found at a frequency of 0.00343 in 1,353,310 control chromosomes in the GnomAD database, including 17 homozygotes. Variant has been reported in ClinVar as Benign (β β ).
Frequency
Genomes: π 0.020 ( 17 hom., cov: 0)
Exomes π: 0.0024 ( 0 hom. )
Consequence
RAI1
NM_030665.4 inframe_deletion
NM_030665.4 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.86
Genes affected
RAI1 (HGNC:9834): (retinoic acid induced 1) This gene is located within the Smith-Magenis syndrome region on chromosome 17. It is highly similar to its mouse counterpart and is expressed at high levels mainly in neuronal tissues. The protein encoded by this gene includes a polymorphic polyglutamine tract in the N-terminal domain. Expression of the mouse counterpart in neurons is induced by retinoic acid. This gene is associated with both the severity of the phenotype and the response to medication in schizophrenic patients. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -16 ACMG points.
BP6
Variant 17-17793779-CCAGCAG-C is Benign according to our data. Variant chr17-17793779-CCAGCAG-C is described in ClinVar as [Benign]. Clinvar id is 212015.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-17793779-CCAGCAG-C is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.058 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAI1 | NM_030665.4 | c.867_872del | p.Gln290_Gln291del | inframe_deletion | 3/6 | ENST00000353383.6 | NP_109590.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAI1 | ENST00000353383.6 | c.867_872del | p.Gln290_Gln291del | inframe_deletion | 3/6 | 1 | NM_030665.4 | ENSP00000323074 | P1 | |
RAI1 | ENST00000395774.1 | c.867_872del | p.Gln290_Gln291del | inframe_deletion | 2/2 | 2 | ENSP00000379120 |
Frequencies
GnomAD3 genomes AF: 0.0201 AC: 1582AN: 78808Hom.: 17 Cov.: 0
GnomAD3 genomes
AF:
AC:
1582
AN:
78808
Hom.:
Cov.:
0
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00239 AC: 3041AN: 1274412Hom.: 0 AF XY: 0.00224 AC XY: 1413AN XY: 630338
GnomAD4 exome
AF:
AC:
3041
AN:
1274412
Hom.:
AF XY:
AC XY:
1413
AN XY:
630338
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0203 AC: 1598AN: 78898Hom.: 17 Cov.: 0 AF XY: 0.0202 AC XY: 756AN XY: 37498
GnomAD4 genome
AF:
AC:
1598
AN:
78898
Hom.:
Cov.:
0
AF XY:
AC XY:
756
AN XY:
37498
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 10, 2015 | - - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 01, 2013 | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 19, 2019 | - - |
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 19, 2016 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at